Introduction
============

Hepatocellular carcinoma (HCC) is a major health concern, and the second leading cause of cancer-related death worldwide ([@b1-ol-0-0-9420]). Japanese surgeons have made significant contributions towards improvements in the surgery for HCC ([@b2-ol-0-0-9420]), and 7,000--8,000 patients per year undergo liver resection in Japan ([@b3-ol-0-0-9420]). Moreover, technical improvement in the safety of less invasive laparoscopic liver resection could change the practice of treatment for HCC ([@b4-ol-0-0-9420],[@b5-ol-0-0-9420]). The Barcelona Clinic Liver Cancer (BCLC) classification, which is a staging system combining tumor status and liver function, has been widely endorsed by treatment guidelines for HCC in Western countries ([@b6-ol-0-0-9420]).

Multinodular HCC beyond the Milan criteria without vascular invasion is classified as intermediate in the BCLC classification (BCLC-B), and transarterial chemoembolization (TACE) is recommended as first-line therapy. However, several reports have suggested a survival benefit for liver resection over TACE in patients with HCC in BCLC-B ([@b7-ol-0-0-9420]--[@b9-ol-0-0-9420]), and liver resection for BCLC-B HCC patients has been actively performed, especially in Asian countries such as Japan. Since patients with BCLC-B HCC are a heterogeneous group ([@b10-ol-0-0-9420]), some may indeed benefit from liver resection compared with TACE. However, it is important to accurately identify this subgroup of patients.

Several groups have suggested prognostic factors after resection for BCLC-B HCC; however, many studies included large solitary tumors (≥5 cm in diameter) ([@b11-ol-0-0-9420]--[@b15-ol-0-0-9420]) and reported pathological factors such as microvascular invasion, tumor differentiation, and liver cirrhosis as prognostic factors ([@b12-ol-0-0-9420]--[@b14-ol-0-0-9420],[@b16-ol-0-0-9420],[@b17-ol-0-0-9420]). Since it is difficult to curatively treat extremely large solitary tumors with TACE, complete resection is preferred and the indication for operative treatment is unequivocal. It is impossible to make decisions on the optimal therapy based solely on preoperative pathological factors. Therefore, we believe that studies about risk stratification of BCLC-B HCC should not include patients with solitary tumors and not use pathological factors as prognostic factors.

The purpose of this study was to derive a prognostic model of overall survival based on the pre-treatment tumor characteristics and patients\' statuses, and to identify the subgroup of patients with multinodular HCC in BCLC-B who could benefit from liver resection.

Patients and methods
====================

### Patients

We retrospectively analyzed 65 patients (training cohort) with multinodular HCC classified as BCLC-B among the 447 HCC patients who underwent liver resection at Yamaguchi University Hospital (Yamaguchi, Japan) from January 2000 to December 2014 to derive a prognostic model. Next, the validity of the model was assessed in an independent external validation cohort (n=132) that included 68 patients with multinodular HCC classified as BCLC-B among the 598 patients who underwent liver resection at Osaka University Hospital (Osaka, Japan) from May 1992 to December 2008, as well as 64 patients of 827 patients treated at Osaka International Cancer Institute (Osaka, Japan) from January 1990 to August 2013 in the validation cohort. Subsequently, we compared outcomes of patients with Child Pugh A who underwent liver resection in the training and validation cohorts (n=186) with those of patients with Child Pugh A who underwent TACE at Yamaguchi University Hospital from May 1996 to December 2016 (n=93) (unpublished data).

HCC was diagnosed using contrast-enhanced computed tomography (CT) mainly with early enhancement in arterial phase followed by washout in the portal or late phases, and elevation of tumor markers, such as α-fetoprotein (AFP) or des-γ-carboxy prothrombin (DCP). We included the patients with multinodular HCC in BCLC-B (2 or 3 nodules larger than 3 cm, more than 4 lesions without macrovascular invasion) diagnosed preoperatively or intraoperatively.

The present study was approved by the Institutional Review Boards of each of the three institutes in which data was obtained (Yamaguchi University Hospital, Osaka International Cancer Institute and Osaka University Hospital; protocol no. H29-093) and was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki. The requirement for informed consent was waived as this was a retrospective cohort study.

### Liver resection

The surgical indication for each patient was discussed at a multidisciplinary cancer board at each institute consisting of hepatopancreatobiliary surgeons, hepatologists, and medical oncologists. Residual liver volume were estimated by CT. Liver resection was carried out with or without the intermittent Pringle\'s maneuver ([@b18-ol-0-0-9420]) with intraoperative ultrasonographic guidance. Intraoperative radiofrequency thermal ablation (RFA) or microwave coagulation (MCT) with resection was performed in some patients.

### Follow-up after liver resection

All patients were followed up in the outpatient clinic every 3 months after surgery with assessment of liver function and serum AFP and DCP levels. Enhanced CT or magnetic resonance images were obtained every 3--4 months and further studies with bone scintigraphy or positron emission tomography were performed when extrahepatic recurrence was suspected. For patients with recurrence, TACE, locoregional therapy, liver resection, or systemic chemotherapy with sorafenib were administered depending on tumor spread and liver function.

### Statistical analysis

Categorical variables are presented as numbers and were analyzed by using Fisher exact test or chi-square test as appropriate. Continuous variables are presented as medians and ranges and were compared by using the Mann-Whitney U test. The Kaplan-Meier method was used to calculate recurrence-free and overall survival, and differences were evaluated using the log-rank test. Independent prognostic factors for overall survival were analyzed with the Cox\'s proportional hazard regression model in a stepwise manner. Statistical analyses were performed using Statflex ver. 6 (Artec, Osaka, Japan), and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Characteristics of patients in the training cohort

The median follow-up period after surgery was 37.4 months (range, 4--187 months). The clinicopathologic characteristics of the 65 patients (51 men, 14 women) are shown in [Table I](#tI-ol-0-0-9420){ref-type="table"}. The median age was 68 years old (range, 35--83 years old). Laboratory results showed that 13 patients were positive for hepatitis B virus surface antigen (HBs-Ag), and 42 had antibodies for hepatitis C virus (HCV-Ab). The median preoperative serum AFP and DCP was 32 ng/ml (range, 0.8--239621 ng/ml) and 160 mAU/ml (range, 12--71200 mAU/ml), respectively.

The median tumor diameter and number was 4 cm (range, 1.5--17 cm) and 3 (range 2-uncountable), respectively. Tumors in 13 patients were limited to 1 section, those in 27 patients involved 2 sections, those in 18 patients involved 3 sections and those in 7 patients were involved to 4 sections, and 35 patients (53.8%) had bilobar disease.

Of the 11 patients who underwent pre-operative therapy, 9 underwent TACE and 2 underwent intra-arterial chemotherapy with 5-flurouracil and cisplatin. The response to pre-operative therapy was unsatisfactory in all patients; 2 patients had stable disease while there was disease progression in 9 patients.

Partial resection was performed in 23 patients, segmentectomy in 15, sectionectomy in 9, hemihepatectomy or bisectionectomy in 16, and trisectionectomy in 2. Liver resection with RFA or MCT was performed in 21 patients.

Curative resection without residual tumor was performed in 49 patients and palliative resection with residual tumor in 16 patients.

### Postoperative survival and recurrence in the training cohort

The 1-, 3-, and 5-year overall survival rates of all 65 patients was 95.2, 67.6, and 44.8%, respectively ([Fig. 1A](#f1-ol-0-0-9420){ref-type="fig"}). The median survival was 51.0 months and 35 patients died in the follow-up period. Cancer progression (n=19, 54.3%) was the most frequent cause of death, followed by other diseases (n=8, 22.9%), liver failure (n=4, 11.4%), rupture of varices (n=1, 2.9%), and unknown causes (n=3, 8.6%). The 1-, 3-, and 5-year recurrence-free survival rate of the 49 patients without residual tumor was 70.5, 28.0, and 22.1%, respectively ([Fig. 1B](#f1-ol-0-0-9420){ref-type="fig"}).

Univariate analysis showed liver cirrhosis and microscopic vascular invasion (mVI) to be associated with poorer survival, while tumors \>5 cm, tumor numbers \>3, bilobar disease, and palliative operations with residual tumors were not ([Table I](#tI-ol-0-0-9420){ref-type="table"}).

Next, we analyzed the relationship between overall survival and the sum of the largest tumor\'s diameter and the number of tumors (N+S). The overall survival of patients with N+S ≤8 was significantly better than that of patient with N+S \>8.

Cox\'s regression analysis was used to assess the relationship between pre-operative factors and overall survival with stepwise backward elimination. The following variables were included in the Cox\'s proportional model: age (≥68 vs. \<68 years), sex, preoperative therapy (no vs. yes), positivity for HBs-Ag, positivity for HCV-Ab, albumin level (\>3.5 g/dl vs. ≤3.5 g/dl), prothrombin rate (\>70% vs. ≤70%), platelet count (Plt; \>1.0×10^10^/l vs. ≤1.0×10^10^/l), indocyanine green retention rate at 15 min (≥15% vs. \<15%), tumor size on imaging (≥5 cm vs. \<5 cm), number of tumors on imaging (≥3 vs. \<3), N+S (\>8 vs. ≤8), bilobar disease (no vs. yes), and DCP (≥400 mAU/ml vs. \<400 mAU/ml). Multivariate analysis revealed that positivity for HCV-Ab, Plt ≤1.0×10^10^/l, N+S \>8, and DCP \>400 mAU/ml were independent prognostic factors for overall survival ([Table II](#tII-ol-0-0-9420){ref-type="table"}).

### Prognostic score and overall survival in the training cohort

Subsequently, we allocated 1 point to each prognostic factor, calculated the score for each patient by summing their points, and analyzed the effect of the score on overall survival. The 1-, 3-, and 5-year overall rate and median survival of patients with a score of 0 (n=6) were 100, 80, 80%, and over 10 years (not reached), respectively; for those with a score of 1 (n=25), they were 100, 90.5, 79.5%, and 102.1 months; for those with a score of 2 (n=19), they were 94.4, 72.2, 33.1%, and 51.0 months; for those with a score of 3 (n=14), they were 85.7, 24.5, 0%, and 29.1 months; and for those with a score of 4 (n=1), they were 100, 0, 0%, and not available ([Fig. 2A](#f2-ol-0-0-9420){ref-type="fig"}). The overall survival of patients with a score of 0 was significantly better than those with a score of 3 (P=0.0318). Overall survival in those with a score of 1 was significantly better than in those with scores of 2 and 3 (P=0.0014 and P\<0.0001, respectively). Patients with a score of 2 had significantly better overall survival than those with a score of 3 (P=0.0021). Using a cutoff point of 2, we classified the patients into two groups: score ≤2 (n=50) and score ≥3 (n=15). The 1-, 3-, and 5-year overall rates and median survival of patients in the score ≤2 group were 97.9, 82.0, 59.7%, and 68.3 months, respectively. In the score ≥3 group, they were 86.7, 22.9, 0%, and 29.1 months, respectively ([Fig. 2B](#f2-ol-0-0-9420){ref-type="fig"}). Overall survival in the score ≤2 group was significantly better than in the score ≥3 group (P\<0.0001).

### Prognostic score and overall survival in the validation cohort

The clinicopathological characteristics of the 132 patients in the validation cohort are shown in [Table III](#tIII-ol-0-0-9420){ref-type="table"}. The median follow-up period after surgery was 49.8 months (range, 3.6--201 months). The median age was 65 (range, 31--84) years. The median of preoperative serum AFP and DCP was 28.5 ng/ml (range, 1--33268 ng/ml) and 326 mAU/ml (range, 10--357456 mAU/ml) mAU/ml, respectively.

The median tumor diameter and number of tumors was 4.6 cm (range, 1.6--17 cm) and 2 (range, 2-uncountable), respectively.

Partial resection was performed in 44, segmentectomy in 16, sectionectomy in 9, hemihepatectomy or bisectionectomy in 42, and trisectionectomy in 30.

The 1-, 3-, and 5-year overall rates and median survival of patients in the validation cohort were 97.0, 75.8, 60.5%, and 77.5 months, respectively. A total of 73 patients died during the follow-up period. Cancer progression (n=60, 82.2%) was the most frequent cause of death, followed by other diseases (n=4, 5.5%), liver failure (n=1, 1.4%), and unknown causes (n=8, 11.0%). There was no difference in overall survival between the training and validation cohorts ([Fig. 3](#f3-ol-0-0-9420){ref-type="fig"}; P=0.1030).

The 1-, 3-, and 5-year overall rates and median survival of patients with a score of 0 (n=18) were 94.4, 76.7, 76.7%, and over 10 years (not reached), respectively. For those with a score of 1 (n=47), they were 95.7, 75.9, 54.6%, and 75.5 months. For those with a score of 2 (n=44), they were 88.6, 79.3, 68.4%, and 82.0 months. For those with a score of 3 (n=22), they were 81.8, 55.6, 47.7%, and 49.2 months. For those with a score of 4 (n=1), they were 100, 0, 0%, and not available ([Fig. 2C](#f2-ol-0-0-9420){ref-type="fig"}). Overall survival in patients with a score of 0 was significantly better than in those with a score of 3 (P=0.0243).

Similar to our approach in the training cohort, patients were classified into two groups: Score ≤2 (n=109) and score ≥3 (n=23). The 1-, 3-, and 5-year overall rates and median survival of patients in the score ≤2 group were 92.7, 77.3, 63.5%, and 82.0 months, respectively. For those in the score ≥3 group, they were 82.6, 52.0, 44.6%, and 49.2 months ([Fig. 2D](#f2-ol-0-0-9420){ref-type="fig"}). Overall survival in the ≤2 group was significantly better than that in the ≥3 group (P=0.0164).

### Relationship between prognostic score and microvascular invasion

In the training cohort, the incidence of mVI in patients with a score ≥3 (73.3%) was significantly higher than in those with a score ≤2 (42.0%; P=0.0333). Similarly, the incidence of mVI in patients with a score ≥3 (65.2%) was significantly higher than in those with a score ≤2 (30.3%; P=0.0015) in the validation cohort ([Fig. 4](#f4-ol-0-0-9420){ref-type="fig"}).

### Survival in each subgroup according to treatment modality

Finally, we compared the overall survival of patients with Child-Pugh A in the training and validation cohorts who underwent surgery (n=186) with those of patients with Child-Pugh A who underwent TACE (n=93) (unpublished data). The clinicopathological characteristics of patients in each group are shown in [Table IV](#tIV-ol-0-0-9420){ref-type="table"}. Although the ratio of males to females (surgery: 153 males to 33 females; TACE: 69 males to 24 females; P=0.1153) and positivity of HCV-Ab (surgery: 114; TACE: 58; P=0.8618) were not different, the median age was older in the TACE group \[surgery: 66.0 (range, 31.0--84.0); TACE: 74.2 (range, 48.2--87.8); P\<0.0001\]. Although the median tumor diameter was larger in the surgery group \[surgery: 4.5 cm (range, 1.5--17.0); TACE: 3.7 cm (range, 1.0--8.9); P=0.0002\] and the median of number of tumors was larger in the TACE group \[surgery: 2 (range, 2-uncountable); TACE: 4 (range, 2--11); P\<0.0001\], the proportion of N+S \>8 in each group (surgery: 64; TACE: 39; P=0.2194) was similar. The proportion of patients with Plt ≤1.0×10^10^/l was higher in the TACE group (surgery: 33; TACE: 29; P=0.0109) but that of patients with DCP \>400 mAU/ml was not different (surgery: 82; TACE: 38; P=0.6079).

The 1-, 3-, and 5-year overall rates and median survival of patients who underwent surgery in the score ≤2 group (n=152) were 95.3, 79.1, 62.9%, and 75.5 months, respectively. For those who underwent TACE in the score ≤2 group (n=72), they were 92.7, 58.8, 37.8%, and 48.0 months. The survival was significantly better in patients in the score ≤2 group who underwent surgery (P=0.0094) ([Fig. 5](#f5-ol-0-0-9420){ref-type="fig"}).

In contrast, the survival was not different between surgery (n=34) and TACE (n=21) in the score ≥3 subgroup (median survival: 29.2 vs. 31.1 months; 5-year survival rate: 25.6% vs. 18.0% for surgery vs. TACE, respectively, P=0.8723).

Discussion
==========

The purpose of the present study was to derive a prognostic model of overall survival based on pre-treatment tumor and patient characteristics, and to identify the subgroup of patients with multinodular BCLC-B HCC who could benefit from liver resection. Indeed, we developed a prognostic score based on HCV-Ab status, pre-operative Plt, tumor status (N+S), and DCP level. According to this prognostic score, patients with a score \<2 would benefit more from surgery than from TACE, which provides 5-year survival rate of approximately 30% or median survival of 30--39.7 months for patients with multinodular HCC in Child-Pugh class A ([@b7-ol-0-0-9420],[@b9-ol-0-0-9420],[@b19-ol-0-0-9420]). In contrast, patients with a score ≥3 would benefit from TACE as its outcomes were equivalent to those of surgery while being less invasive. Although mVI is the most widely recognized prognostic factor after liver resection ([@b13-ol-0-0-9420],[@b14-ol-0-0-9420],[@b16-ol-0-0-9420],[@b17-ol-0-0-9420],[@b20-ol-0-0-9420]), it is impossible to determine pre-operatively. As our prognostic score was associated with the frequency of mVI, it could also be useful for predicting its presence pre-operatively.

Some reports have shown that tumor size and number are prognostic factors ([@b12-ol-0-0-9420],[@b16-ol-0-0-9420],[@b21-ol-0-0-9420]). Although either of these variables alone tended to be associated with the outcome of patients in univariate analyses, multivariate analysis showed that N+S had a stronger effect. Recently, we have shown that the mathematical product of maximum tumor size and number of tumors (NxS) was an important prognostic factor after curative liver resection for HCC ([@b22-ol-0-0-9420]). The 'metro ticket' ([@b23-ol-0-0-9420],[@b24-ol-0-0-9420]) and up-to-seven criteria ([@b25-ol-0-0-9420]) for liver transplantation for HCC, the subclassification ([@b26-ol-0-0-9420]) and NSP ([@b27-ol-0-0-9420]) score of BCLC-B HCC for surgery, and the 4 of 7 cm classification ([@b19-ol-0-0-9420]) of BCLC-B HCC for TACE all emphasize that both tumor size and number is a critical prognostic factor for several treatments for HCC. These results have shown that the sum of maximum tumor size and number of tumors reflect individual tumor characteristics more precisely than either variable by itself. We changed the cutoff point of N+S and analyzed survival using univariate analyses in a step by step manner (data not shown). Because an N+S \>8 had the strongest effect on survival in this analysis, we selected this cutoff point as a covariate in the Cox regression analysis. The up-to-seven criteria have been the most popular cutoff point in liver transplantation for HCC exceeding the Milan criteria. Although the optimal cutoff point could change in different cohorts, N+S could be a stronger prognostic factor than tumor size or number by themselves.

Some studies have shown that DCP was a prognostic factor after liver resection for HCC ([@b16-ol-0-0-9420],[@b28-ol-0-0-9420]) and that it correlated with an aggressive phenotype and mVI ([@b29-ol-0-0-9420]). Similar to these results, DCP was one of the independent prognostic factors for survival in this study.

Liver function is also an important prognostic factor after hepatic resection ([@b16-ol-0-0-9420],[@b22-ol-0-0-9420]). We demonstrated here that a Plt count \<10^10^/l was one such prognostic factor. Plt count and the aspartate aminotransferase to Plt ratio index have been reported as independent predictors of survival after liver resection for HCC ([@b30-ol-0-0-9420],[@b31-ol-0-0-9420]). These results may suggest that multiple HCCs and poor functional reserve are relative contraindications to liver resection, as Ishizawa *et al* ([@b16-ol-0-0-9420]) had reported earlier.

We acknowledge several limitations to this study. First, it was a retrospective study with a limited number of patients. Second, we could not compare the outcomes of patients underwent surgery and TACE with propensity score matching due to the small number of cases. Although the outcomes of patients who underwent liver resection were compared with those that underwent TACE in this study, bias due to patient selection may have been present. However, this study is potentially important for evaluating the effectiveness of liver resection for multinodular intermediate stage HCC as it excludes patients with large solitary tumors. Furthermore, the consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting stated that randomization of patients into surgery or TACE is difficult because of patient risks and ethical reasons ([@b32-ol-0-0-9420]). In this situation, clinicians should make their treatment decisions after referring to previous retrospective analyses. Third, the study period of this analysis was relatively long. Treatment strategies and combinations of multimodality therapies could have changed during this long period; however, this could not be avoided as we attempted to identify prognostic factors in such a small cohort as BCLC-B HCC patients. Further investigation is needed to determine pre-treatment factors that can help clinicians select the appropriate treatment for each patient.

In conclusion, liver resection for selected patients with BCLC-B HCC is feasible and can promote long-term survival. HCV-Ab status, preoperative Plt count, preoperative DCP level, and N+S could be useful for patient selection.
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![Overall and disease-free survival following liver resection in patients with Barcelona Clinic Liver Cancer-B hepatocellular carcinoma in training cohort. (A) Overall survival of 65 patients who underwent liver resection. (B) Disease-free survival of 49 patients who underwent liver resection without residual tumor.](ol-16-05-6383-g00){#f1-ol-0-0-9420}

![Overall survival following liver resection based on the prognostic score. (A) The surgical outcome of patients in the training cohort based on the prognostic score. The overall survival of patients with a score of 1 (blue line) was significantly better than those with a score of 2 (orange line, P=0.0001) or 3 (red line, P\<0.0001), and those who scored 2 fared significantly better than those who scored 3 (P=0.0255). (B) The surgical outcome of the two groups of patients (score ≤2 vs. ≥3) in the training cohort. Overall survival of patients with a score ≤2 (solid black line) was significantly better than those with a score ≥3 (dotted line; P\<0.0001). (C) The surgical outcome of patients in the validation cohort based on our prognostic score. The overall survival of patients with a score of 0 (black line) was significantly better than those with a score of 3 (red line, P=0.0243). (D) The surgical outcome of the two groups of patients (score ≤2 vs. ≥3) in the validation cohort. Overall survival of patients with a score ≤2 (solid black line) was significantly better than those with a score ≥3 (dotted line; P=0.0164).](ol-16-05-6383-g01){#f2-ol-0-0-9420}

![Overall survival following liver resection in the training and validation cohorts.](ol-16-05-6383-g02){#f3-ol-0-0-9420}

![Correlation between the prognostic score and incidence of microvascular invasion in the training and validation cohorts. The incidence of microvascular invasion in patients with a score ≥3 was significantly higher than in those with a score ≤2 in each cohort.](ol-16-05-6383-g03){#f4-ol-0-0-9420}

![Overall survival of patients with Child-Pugh A in each subgroup according to treatment modalities. In patients with a score ≤2, the survival of patients who underwent surgery (solid line) was significantly better than those underwent TACE (dotted line; P=0.0094). By contrast, the survival was not different between surgery (dashed line) and TACE (dashed-dotted line) in the score ≥3 subgroup. TACE, transarterial chemoembolization.](ol-16-05-6383-g04){#f5-ol-0-0-9420}

###### 

Clinicopathological characteristics and overall survival of the 65 patients in the training cohort.

  Variable                        n     1-year   3-year   5-year   P-value
  ------------------------------- ----- -------- -------- -------- ---------
  Age, years                                                       
    \<68                          29    93.1     61.7     51.7     0.4897
    ≥68                           36    97.1     72.4     40.1     
  Sex                                                              
    Male                          51    93.9     67.7     47.8     0.0929
    Female                        14    100      67.1     28       
  HBs-Ag                                                           
    Negative                      52    98       69.4     44       0.4595
    Positive                      13    84.6     60.6     50.5     
  HCV-Ab                                                           
    Negative                      23    90.9     72.1     65.6     0.3263
    Positive                      42    97.5     65.3     35       
  Prothrombin rate, %                                              
    ≤70                             3   100      66.7     33.3     0.2581
    \>70                          62    95       67.6     45.4     
  Albumin level, g/dl                                              
    ≤3.5                          24    91.3     64.1     29.4     0.1551
    \>3.5                         41    97.4     69.5     53.1     
  Platelet count, /µl                                              
    ≤1.0×10^5^                    18    94.1     41.2     11.8     0.0001
    \>1.0×10^5^                   47    95.6     78.4     59.9     
  ICGR15, %                                                        
    \<15                          28    96.3     76.8     53.3     0.1811
    ≥15                           37    94.4     60.7     38.7     
  Child-Pugh                                                       
    5                             37    97.1     68.6     53.4     0.0873
    6                             27    92.3     68.4     34.6     
    7                               1   100      0        0        
  Tumor size on image, cm                                          
    \<5                           45    100      74.9     54.4     0.0563
    ≥5                            20    85       52.2     22.4     
  Number of tumors on image                                        
    2                             25    100      73.1     48.8     0.1636
    ≥3                            40    92.4     64.4     42.8     
  Tumor size + number of tumor                                     
    ≤8                            42    100      78.3     50.9     0.0415
    \>8                           23    87       49       35       
  Liver cirrhosis                                                  
    Absent                        31    93.3     79.4     54.3     0.0307
    Present                       34    97       56.1     35.6     
  AFP, ng/ml                                                       
    \<400                         50    97.9     70.2     45.2     0.5982
    ≥400                          15    86.7     59.3     42.3     
  DCP, mAU/ml                                                      
    \<400                         39    100      78       58.6     0.0047
    ≥400                          26    88.5     53.1     27.2     
  Bilobar disease                                                  
    No                            30    100      69.4     39       0.9002
    Yes                           35    91.3     66.2     50.7     
  Histologic grade                                                 
    Well-moderate                 57    94.5     64.4     42       0.9984
    Poor                            8   100      87.5     62.5     
  Microscopic vascular invasion                                    
    Absent                        33    100      79.4     61.2     0.0400
    Present                       32    90.2     56       30.2     
  Intrahepatic metastasis                                          
    Absent                        35    97       70       46.4     0.3759
    Present                       30    93.3     65.7     43.7     
  Residual tumor                                                   
    Absent                        49    97.8     66.8     47.6     0.0590
    Present                       16    87.5     68.8     35.7     
  Preoperative therapy                                             
    No                            53    96.1     70.9     47.5     0.1821
    Yes                           11    90.9     54.6     34.1     

HBs-Ag, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; ICGR, indocyanine green retention rate at 15 min; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin.

###### 

Multivariable Cox-regression analysis of overall survival.

  Variable              RR      95% CI         P-value
  --------------------- ------- -------------- ---------
  HCV-Ab                                       
    Negative            1                      
    Positive            3.193   1.274--8.000   0.0132
  Platelet count, /µl                          
    ≤1.0×10^5^          1                      
    \>1.0×10^5^         3.785   1.764--8.121   0.0006
  N+S                                          
    ≤8                  1                      
    \>8                 3.614   1.670--7.820   0.0011
  DCP, mAU/ml                                  
    ≤400                1                      
    \>400               3.556   1.664--7.599   0.0011

RR, relative risk; CI, confidence interval; HCV-Ab, hepatitis C virus antibody; N+S, sum of largest tumor diameter (cm) and number of tumors; DCP, des-γ-carboxy prothrombin.

###### 

Clinicopathological characteristics and overall survival in the 132 patients of the validation cohort.

  Variable                        n      1-year   3-year   5-year   P-value
  ------------------------------- ------ -------- -------- -------- ---------
  Age, years                                                        
    \<68                            84   91.7     74.2     60.7     0.9019
    ≥68                             48   89.6     71.4     60.4     
  Sex                                                               
    Male                          110    92.7     73.4     60.9     0.7961
    Female                          22   81.8     71.8     59.8     
  HBs-Ag                                                            
    Negative                      104    91.4     76.9     60.7     0.4944
    Positive                        28   89.3     59.4     59.4     
  HCV-Ab                                                            
    Negative                        56   89.3     66.7     56.3     0.8623
    Positive                        76   92.1     77.9     63.5     
  Prothrombin rate, %                                               
    ≤70                             21   90.5     65.2     54.3     0.6857
    \>70                          111    91       74.7     61.8     
  Albumin level, g/dl                                               
    ≤3.5                            40   85       71.5     52.2     0.2968
    \>3.5                           92   93.5     74       63.9     
  Platelet count, /µl                                               
    ≤1.0×10^5^                      19   89.5     69.8     69.8     0.9496
    \>1.0×10^5^                   113    91.2     73.7     59.6     
  ICGR15, %                                                         
    \<15                            75   90.7     75.2     68.7     0.0095
    ≥15                             57   91.2     70.7     50       
  Child-Pugh                                                        
    5                               83   92.8     73.5     63.6       \>0.5
    6                             39     89.7     73.8     55.6     
    7                               10   80       68.6     54.9     
  Tumor size on image, cm                                           
    \<5                             67   94       84.1     69.4     0.0462
    ≥5                              65   87.7     62.2     51.5     
  Number of tumor on image                                          
    2                               89   93.3     78.2     66.7     0.0447
    ≥3                              43   86.1     62.2     46.3     
  Tumor size + number of tumor                                      
    ≤8                              85   96.5     84       68.8     0.0005
    \>8                             47   80.9     53.1     45       
  AFP, ng/ml                                                        
    \<400                         106    93.4     77.5     63.4     0.1945
    ≥400                            26   80.8     55.5     49.9     
  DCP, mAU/ml                                                       
    \<400                           69   92.8     75.6     65       0.171
    ≥400                            63   88.9     70.7     55.9     
  Histologic grade                                                  
    Well-moderate                   91   95.6     75.7     63.9     0.6236
    Poor                            41   80.5     67.6     53.1     
  Microscopic vascular invasion                                     
    Absent                          84   94.1     76.6     65.6     0.1604
    Present                         48   85.4     67.2     51.6     

HBs-Ag, hepatitis B surface antigen; HCV-Ab, hepatitis C virus antibody; ICGR, indocyanine green retention rate at 15 min; AFP, a-fetoprotein; DCP, des-γ-carboxy prothrombin.

###### 

Clinicopathologic characteristics of patients who underwent surgery or TACE.

  Variable                       Surgery (n=186)     TACE (n=93)         P-value
  ------------------------------ ------------------- ------------------- ----------
  Age, years                     66.0 (31.0--84.0)   74.2 (48.2--87.8)   \<0.0001
  Sex                                                                    
    Male                         153                 69                  0.1153
    Female                       33                  24                  
  HCV-Ab                                                                 
    Negative                     72                  35                  0.8618
    Positive                     114                 58                  
  Tumor size on image, cm        4.5 (1.5--17.0)     3.7 (1.0--8.9)      0.00018
  Number of tumors on image      2 (2-uncountable)   4 (2--11)           \<0.0001
  Tumor size + number of tumor                                           
    ≤8                           122                 54                  0.2194
    \>8                          64                  39                  
  Platelet count, /µl                                                    
    ≤1.0×10^5^                   33                  29                  0.0109
    \>1.0×10^5^                  153                 64                  
  DCP, mAU/ml                                                            
    \<400                        104                 55                  0.6079
    ≥400                         82                  38                  
  Prognostic score                                                       
    ≤2                           152                 72                  0.3946
    ≥3                           34                  21                  

HCV-Ab, hepatitis C virus antibody; DCP, des-γ-carboxy prothrombin; TACE, transarterial chemoembolization.
